Aug 19, 2026 —
As the next generation of chimeric antigen receptor (CAR) T-cell therapies moves toward broader commercialization, industry leaders say expanding patient access will depend on advancing both ex vivo and in vivo approaches in parallel rather than choosing between them.
Improvements in manufacturing, automation, and vector engineering are expected to address long-standing challenges around cost, scalability, and turnaround time that have limited access to cell therapies. In vivo strategies, which aim to generate CAR T cells directly inside the patient, could reduce reliance on complex ex vivo manufacturing, while continued automation of ex vivo production is expected to improve consistency and throughput.
The trajectory underscores the central role of scalable manufacturing and high-quality viral vectors in bringing cell and gene therapies to more patients.
